Existing and investigational combination drug therapy for high-density lipoprotein cholesterol

American Journal of Cardiology

Volumn 90, Issue 10 SUPPL. 2, 2002, Pages 30-43

  Bays, Harold ^a  

^a Louisville Metabolic and Atherosclerotic Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID 2 (3 NEOPENTYL 3 NONYLUREIDO)CYCLOHEXYL ESTER; ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; AVASIMIBE; CERIVASTATIN; CHLORTALIDONE; CHOLESTEROL ESTER TRANSFER PROTEIN; CONJUGATED ESTROGEN; DOXAZOSIN; ESTROGEN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GESTAGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PACTIMIBE; PHENYTOIN; PRAVASTATIN; PROTEIN INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART VENTRICLE ARRHYTHMIA; HUMAN; LUNG EMBOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037146189     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02971-5     Document Type: Article

References (52)

1. Gotto A.M. Contemporary Diagnosis and Management of Lipid Disorders. 2nd ed. 2000;Handbooks in Health Care Company, Newtown, PA. 1999.
2. Lipid Research Clinics Program the Lipid Research Clinics Coronary Primary Prevention Trial results . JAMA. 25:(1):1984;351-374.
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 334:1994;1383-1389.
4. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomized placebo-controlled trial . Lancet. 360:2002;7-22.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
6. Manninen V., Koskinen P., Manttari M., Huttunen J., Canter D., Frick H. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Frederickson type IIa subjects in the Helsinki Heart Study. Am J Cardiol. 66:1990;24A-27A.
7. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schafer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
8. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease expert group recommendations . Am J Cardiol. 90:2002;139-143.
9. Tavintharan S., Kashyap M.L. The benefits of niacin in atherosclerosis. Curr Atheroscler. 3:2001;74-82.
10. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
11. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effects of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 88:2001;270-274.
12. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D., Bays H.E., Simmons P.D. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 89:2002;672-678.
13. Bays H.E., McGovern M.E., Simmons P.D. Lipoprotein effects of a new dual component drug (extended-release niacin/lovastatin) compared to starting doses of atorvastatin and simvastatin. J Am Coll Cardiol. 39:(suppl A):2002;245A. [oral contributions].
14. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., Kostis J.B., Sheps D.S., Brinton E.A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease the ADMIT study. A randomized trial . JAMA. 284:2000;1263-1270.
15. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., Ganda O.P., Rosenson R.S., Buse J.B., Robertson D.D., Sheehan J.P. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 162:2002;1568-1576.
16. Ellen R.L., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 81:1998;60B-65B.
17. Bays H.E., Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Saf. 19:1998;355-371.
18. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Pearson P.G., Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051.
19. Prueksaritanont Tsubramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., Baillie T.A. Glucoronidation of statins in animals and humans a novel mechanism of statin lactonization . Drug Metab Dispos. 30:2002;505-512.
20. Diabetes Trial Unit, University of Oxford 2002: Available at: http://www.dtu.ox.ac.uk.
21. Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 23:(suppl 2):2000;B49-B53.
22. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 288:2002;49-57.
23. Hulley S., Furberg C., Barrett-Connor E., Cauley J., Grady D., Haskell W., Knopp R., Lowery M., Satterfield S., Schrott H., Vittinghoff E., Hunninghake D. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 288:2002;58-66.
24. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 288:2002;321-333.
25. Pressel S.L., Davis B.R., Wright J.T., Geraci T.S., Kingry C., Ford C.E., Piller L.B., Bettercourt J., Kimmel B., Lusk C., et al. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 22:2001;29-41.
26. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
27. Jones P., Kafonek S., Hunninghake D. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.
28. Davidson M.H. Rosuvastastin a highly efficacious statin for the treatment of dyslipidaemia . Expert Opin Investig Drugs. 11:2002;125-141.
29. Bays H.E., Hunninghake D., Chitra R., Carbarns I. More patients achieve national Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals with rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. [poster] Presented at: American Heart Association Pacific Scientific Forum. 42nd Annual Conference on Cardiovascular Disease: Epidemiology and Prevention; April:2002;. Honolulu, Hawaii.
30. Brown W.V., Zedler B.K., Bays H.E., Hassman H.A., Chitra R.R., Miller E. Long-term efficacy and safety of rosuvastastin results of a 52-week comparator-controlled trial versus pravastatin and simvastatin . [abstract] Eur Heart J. 22:(suppl):2001;270. Abstract 1526.
31. Olsson A., Southworth H., Wilpshaar J.W. Long-term efficacy and safety of rosuvastatin results of a 52-week comparator-controlled trial versus atorvastatin . Eur Heart J. 22:(suppl):2001;254. Abstract 1410.
32. Stein E., Strutt K.L., Miller E., Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 37:(suppl A):2001;292A. Abstract 1261-176.
33. Bays H.E., Dujovne C.A. Lipid-altering drugs in development. Drugs Res Dev. 1:1999;463-469.
34. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary artery disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 97:1996;2917-2923.
35. Pfizer Sees Sustained, Strong Performance as Broad and Deep Product Line, New Product Pipeline, Profit Margin Expansion and Strategic Alliances Drive Growth. Press release. December 11, 2000. Available at: http://www.pfizer.com.
36. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112.
37. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., Knopp R.H., Lipka L.J., Lebeaut A.P., Yang B., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia pooled analysis of two phase II studies . Clin Ther. 23:2001;1209-1230.
38. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L., LeBeaut A., Suresh R., Sun S., Veltri E. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. [poster session abstract] J Am Coll Cardiol. 39:(suppl A):2002;226A.
39. Ballantyne C., Houri J., Notarbartolo A., Melani L., Lipka L., LeBeaut A., Suresh S., Sun S. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. [poster session abstract] J Am Coll Cardiol. 39:(suppl A):2002;227A.
40. Melani L., Mills R., Hassman D., Lipetz R., Lipka L, LeBeaut A., Suresh R., Mukhopadhyay P. Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl B):2002;139B.
41. Lipka L., Kerzner B., Corbelli J., Sharp S., Melani L., LeBeaut A., Suresh R., Veltri E. Ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl B):2002;430B.
42. Bays H.E., Weiss S., Gagne C., Mata P., Gumbiner B., Melino M., Quinto K., Cho M. Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia oral contributions. J Am Coll Cardiol. 39:(suppl A):2002;245A.
43. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanisms of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
44. Gervois P., Torra I.P., Fruchart J.C., Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med. 38:2000;3-11.
45. MacDougall D., Nyberg J., Bays H., Dujovne C. Efficacy and tolerability of a novel lipid-altering agent, CI-1027, in patients with low high density lipoprotein cholesterol and normal or elevated triglycerides. Abstract presented at the Cardiovascular Pharmacotherapy Congress; May 19:2002;. Montreal, Quebec, Canada.
46. Miller N.E. Pharmacotherapy of disorders of plasma lipoprotein metabolism. Am J Cardiol. 66:1990;16A-19A.
47. Winkler K., Schaefer J.R., Klima B., Nuber C., Friedrich I., Koster W., Gierens H., Scharnagl H., Soufi M., Wieland H., Marz W. HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis. 150:2000;113-120.
48. Locker P.K., Jungbluth G.L., Francom S.F., Hughes G.S. Lifibrol a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group . Clin Pharmacol Ther. 57:1995;73-88.
49. Li L., Pownall H.J. Effects of high-density lipoprotein (2) on cholesterol transport and acyl-coenzyme A cholesterol acyltransferase activity in P388D1 macrophages . Biochim Biophys Acta. 1530:2001;111-122.
50. Hirakawa Y., Shimokawa H. Lipid-lowering drugs. Nippon Yakurigaku Zasshi. 118:2001;389-395.
51. Matsuda K. ACAT inhibitors as antiatherosclerotic agents compounds and mechanisms . Med Res Rev. 14:1994;271-305.
52. Insull W., Koren M., Davignon J., Sprecher D., Schrott H., Keilson L.M., Brown A.S., Dujovne C.A., Davidson M.H., McLain R., Heinonen T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins in patients with combined hyperlipidemia. Atherosclerosis. 157:2001;137-144.